Trial
NCT01828476
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rutgers, The State University of New Jersey
Collaborators
Rutgers Cancer Institute of New Jersey; National Cancer Institute (NCI); AbbVie
Condition
Prostate Cancer
Intervention
Abiraterone
Why stopped
The Investigator left the organization.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-04